Clinical Trials for Ovarian Cancer

A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with CLDN6-positive advanced solid tumors—emphasizing platinum-resistant/refractory ovarian cancer (also endometrial or testicular)—with measurable disease and ECOG 0–2 receive weekly IV CTIM-76, a CLDN6×CD3 T cell–engaging bispecific antibody, in dose escalation and expansion cohorts. Excludes active/untreated CNS disease, prior CLDN6 therapy, uncontrolled infection; treatment continues until progression or toxicity.

ClinicalTrials.gov ID: NCT06515613

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults (≥18; ≥15 for germ cell tumors) with CLDN6-positive advanced ovarian/fallopian tube/primary peritoneal cancer, endometrial adenocarcinoma, or germ cell tumors after standard therapy receive XmAb541, an investigational CLDN6×CD3 bispecific T‑cell–engaging antibody given IV or SC with step-up dosing. Excludes prior CLDN6-directed therapy, platinum-refractory ovarian cancer or rapid progression on ≥2nd-line, uncontrolled CNS metastases, active autoimmune disease, and significant comorbidities.

ClinicalTrials.gov ID: NCT06276491

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.

ClinicalTrials.gov ID: NCT03968406

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with recurrent, platinum-resistant epithelial ovarian cancer whose tumors are TAG72-positive receive lymphodepleting fludarabine/cyclophosphamide followed by a single intraperitoneal infusion of autologous TAG72-directed CAR T cells. Investigational therapy targets the TAG72 glycoprotein to mediate CAR T–cell killing of peritoneal ovarian cancer; single-arm dose-escalation with long-term follow-up.

ClinicalTrials.gov ID: NCT05225363

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Single-arm study for adults with recurrent primary mucinous ovarian cancer (ECOG 0–2) undergoing secondary cytoreductive surgery followed by intraoperative HIPEC using cisplatin. Aims to improve progression-free survival with a locoregional approach (heat-enhanced, DNA crosslinking cytotoxic agent) while evaluating perioperative toxicity and quality of life.

ClinicalTrials.gov ID: NCT05123807

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (post‑bevacizumab; BRCA‑mutated must have prior PARP inhibitor) receive outpatient lymphodepleting cyclophosphamide/fludarabine followed by three intraperitoneal doses of FT536, an off‑the‑shelf iPSC‑derived CAR NK product targeting the α3 domain of MICA/MICB with enhanced ADCC (high‑affinity non‑cleavable CD16), IL‑15/IL‑15Rα support, and CD38 knockout. Treatment is delivered via intraperitoneal catheter across dose‑escalation cohorts; patients must be fit for lymphodepletion and long‑term follow‑up for gene‑modified cell therapy.

ClinicalTrials.gov ID: NCT06342986

Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent platinum-resistant or -refractory high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (ECOG 0–2) receive lymphodepleting cyclophosphamide/fludarabine followed by a single intraperitoneal infusion of autologous B7-H3 (CD276)–targeted CAR T cells incorporating an inducible caspase-9 safety switch (rimiducid-activatable). Single-arm dose-escalation with intraperitoneal port/catheter; serial biopsies required.

ClinicalTrials.gov ID: NCT06305299

A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Single-arm study in adults with platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1, measurable disease, ≥2 prior lines, PARPi if BRCA1/2+) receiving OPB-101, an autologous mesothelin-directed CAR T cell therapy with antigen-dependent OUTSMART IL-2/15 cytokine expression and an EGFR-based safety switch. Evaluates dose escalation/expansion to define safety and RP2D.

ClinicalTrials.gov ID: NCT07030907

A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal, or select sex cord-stromal tumors (platinum-resistant/refractory after ≥1 platinum and ≥2 prior systemic regimens; measurable/detectable disease; ECOG 0–2) receive a single infusion of autologous T cells engineered with a chimeric endocrine receptor targeting FSHR, delivered intraperitoneally or intravenously across escalating dose levels. Investigational product: FSHR-targeted CAR-like T cells designed for antigen-directed activation/cytotoxicity against FSHR-expressing tumors.

ClinicalTrials.gov ID: NCT05316129

An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced solid tumors refractory to standard therapy receive oral STP938 (dencatistat), a first‑in‑class selective CTPS1 inhibitor, in dose escalation; a safety expansion enrolls patients with CTPS2-null ovarian cancer to exploit a synthetic-lethal vulnerability. Key exclusions include active CNS disease and significant immunosuppression.

ClinicalTrials.gov ID: NCT06297525